期刊文献+

手工免疫组化检测非小细胞肺癌ALK蛋白表达的对比分析 被引量:6

Comparative study of ALK antibody with manual and automatic immunohistochemical detection in non-small cell lung cancer
下载PDF
导出
摘要 目的探讨手工免疫组化(immunohistochemistry,IHC)法检测不同克隆号ALK抗体在间变性淋巴瘤激酶(anaplastie lymphoma kinase,ALK)融合的非小细胞肺癌(non-small cell lung cancer,NSCLC)中ALK蛋白表达,并与全自动免疫组化染色法进行比较。方法选取60例NSCLC石蜡样本,运用4种抗体D5F3(Ventana)、D5F3(Cell Signaling)、1A4/1H7(Ori Gene)、5A4(Abcam)联合常规手工IHC分别检测NSCLC中ALK蛋白水平,与抗体D5F3(Ventana)采用全自动IHC(Bench Mark)结果进行对比分析。结果 D5F3(Ventana+Bench Mark)检测发现ALK融合阳性NSCLC者32例,ALK融合阴性NSCLC者28例,经FISH法验证结果一致。采用手工IHC法检测4种抗体D5F3(Ventana)、D5F3(Cell Signaling)、1A4/1H7、5A4染色灵敏性分别为93.8%、84.4%、93.8%、56.3%,特异性均为100%,与D5F3(Ventana+Bench Mark)染色结果的一致性分别为96.7%、91.7%、96.7%、76.7%。手术切除大标本的ALK表达优于活检小标本。结论手工IHC法简便经济、易于普及,选择高灵敏性、特异性的抗体,可用于中小医院临床筛查ALK融合NSCLC,染色阳性病例再行抗体D5F3(Ventana)全自动IHC或FISH法检测。 Purpose To explore the immunohistochemical (IHC) expression of ALK antibodies with different clones in anaplastic lym- phoma kinase (ALK) gene fusion non-small cell lung cancer (NSCLC). Methods ALK expression in 60 NSCLCs were detected by IHC including autostainer (DSF3, Ventana + BenchMark) and manual staining using 4 different antibodies of DSF3 (Ventana) , DSF3 (Cell Signaling) , 1A4/1H7 (OriGene), 5A4 (Abeam) , and all cases were verified with ALK FISH. Their expressions with 4 anti- bodies were compared with those by D5F3 (Ventana + BenchMark). Results 32 ALK gene rearrangement NSCLCs and 28 negative cases were identified by FISH and DSF3 (Ventana + BenchMark). The sensitivity of DSF3 (Ventana) , DSF3 (Cell Signaling) , 1A4/ 1H7 (OriGene), 5A4 (Abcam) was 93.8%, 84.4%, 93.8%, 56.3%, and all the speciticity was 100%. The consistency with D5F3 (Ventana + BenchMark) was 96. 7% , 91.7% , 96. 7% and 76.7% , respectively. The validity of immunohistochemical staining in surgical resection specimens was better than in small biopsies. Conclusion Effective routine manual immunohistochemistry with high-affinity antibody clone may provide a more economic and widespread pre-screening technique.
出处 《临床与实验病理学杂志》 CAS CSCD 北大核心 2015年第3期268-272,共5页 Chinese Journal of Clinical and Experimental Pathology
基金 国家自然科学基金(81171391 81372743)
关键词 肺肿瘤 非小细胞肺癌 间变性淋巴瘤激酶 免疫组织化学 筛查 lung neoplasm non-small cell lung cancer ALK immunohistoehemistry screening
  • 相关文献

参考文献18

  • 1Fu S, Wang F, Shao Q, et al. Detection of EML4-ALK fusion gene in chinese non-small cell lung cancer by using a sensitive quantitative real-time reverse transcriptase PCR technique[J]. Diagn Mol Pathol, 2014. [Epub ahead of print].
  • 2Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012[J]. CA Cancer J Clin, 2012,62(1):10-29.
  • 3张绪超,陆舜,张力,王长利,程颖,李甘地,Tony Mok,Mok,黄诚,刘晓晴,王洁,王孟昭,张沂平,周建英,周晓燕,林冬梅,杨衿记,李慧,陈海泉,钟文昭,吴一龙.中国间变性淋巴瘤激酶(ALK)阳性非小细胞肺癌诊断专家共识(2013版)[J].中华病理学杂志,2013,42(6):402-406. 被引量:93
  • 4Zhou J, Zhao J, Sun K, et al. Accurate and economical detection of ALK positive lung adenocarcinoma with semiquantitative immunohistochemical screening[J]. PLoS One, 2014,9(3):e92828.
  • 5Hutarew G, Hauser-Kronberger C, Strasser F, et al. Immunohistochemistry as a screening tool for ALK rearrangement in NSCLC: evaluation of five different ALK antibody clones and ALK FISH[J]. Histopathology, 2014,65(3):398-407.
  • 6Soda M, Choi Y L, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer[J]. Nature, 2007,448(7153):561-6.
  • 7Shackelford R E, Vora M, Mayhall K, et al. ALK-rearrangements and testing methods in non-small cell lung cancer: a review[J]. Genes Cancer, 2014,5(1-2):1-14.
  • 8Gorczynski A, Prelowska M, Adam P, et al. ALK-positive cancer: still a growing entity[J]. Future Oncol, 2014,10(2):305-21.
  • 9Lindeman N I, Cagle P T, Beasley M B, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the college of american pathologists, international association for the study of lung cancer, and association for molecular pathology[J]. J Mol Diagn, 2013,15(4):415-53.
  • 10Desai S S, Shah A S, Prabhash K, et al. A year of anaplastic large cell kinase testing for lung carcinoma: pathological and technical perspectives[J]. Indian J Cancer, 2013,50(2):80-6.

二级参考文献31

  • 1Soda M,Choi YL,Enomoto M,et al.Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.Nature,2007,448(7153):561-566.
  • 2Wong DW,Leung EL,So KK,et al.The EML4 ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.Cancer,2009,115(8):1723-1733.
  • 3Shaw AT,Yeap BY,Mino-Kenudson M,et al.Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.J Clin Oncol,2009,27(26):4247-4253.
  • 4Shaw AT.Phase 3 randomized study of crizotinib versus pemetrexed or docetaxel chemotherapy in advanced,ALK-positive NSCLC (PROFILE 1007).35th ESMO,2012,abstract LBA1.
  • 5全国肿瘤防治研究办公室/全国肿瘤登记中心/卫生部疾病预防控制局.2009全国肿瘤登记年报.北京:军事医学科学出版社.2010.
  • 6Rikova K,Guo A,Zeng Q,et al.Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.Cell,2007,131 (6):1190-1203.
  • 7Mitsudomi T,Suda K,Tomizawa K,et al.Clinico-pathologic features of lung cancer with EML4-ALK translocation.J Clin Oncol,2010 (suppl):abstr 10598.
  • 8Zhang X,Zhang S,Yang X,et al.Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.Mol Cancer,2010,9:188.
  • 9Wu SG,Kuo YW,Chang YL,et al.EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wildtype EGFR.J Thorac Oucol,2012,7(1):98-104.
  • 10Rodig SJ,Mino-Kenudson M,Dacic S,et al.Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.Clin Cancer Res,2009,15(16):5216-5223.

共引文献94

同被引文献42

  • 1周小鸽.免疫组化染色过程中存在的问题及对策[J].诊断病理学杂志,2004,11(4):211-213. 被引量:19
  • 2Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EMIA-ALK fusion gene in non-small-cell lung cancer [J]. Nature, 2007, 448(7153): 561-566.
  • 3Shaw AT, Yeap BY, Solomon B J, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK generearrangement: a retrospective analysis[J]. Lancet Oncol, 2011, 12(11): 1004-1012.
  • 4Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012[J]. CA Cancer J Clin, 2012, 62(1): 10-29.
  • 5Minca EC, Portier BP, Wang Z, et al. ALK status testing in non- small cell lung carcinoma: correlation between uhrasensitive IHC and FISH[J]. J Mol Diagn, 2013, 15(3): 341-346. DOh 10.1016/j. jmoldx.2013.01.004.
  • 6Yi ES, Boland JM, Maleszewski JJ, et al. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithmfor FISH[J]. J Thorac Oncol, 2011, 6(3): 459-465. DOh lO.1097/JTO.0bO13e318209edb9.
  • 7Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology[J]. J Mol Diagn, 2013, 15(4): 415-453. DOh 10.1016/j.jmoldx.2013.03.001.
  • 8Hutarew G, Hauser- Kronberger C, Strasser F, et al. Immunohistochemistry as a screening tool for ALK rearrangement in NSCLC: evaluation of five different ALKantibody clones and ALK FISH[J]. Histopathology, 2014, 65(3): 398-407. DOh 10. 1111/his.12399.
  • 9穆清爽,韩利梅.维吾尔民族非小细胞肺癌组织中的ERCC1、BRCA1的表达及预后关系的研究[J].重庆医科大学学报,2011,36(10):1197-1201. 被引量:2
  • 10张绪超,陆舜,张力,王长利,程颖,李甘地,Tony Mok,Mok,黄诚,刘晓晴,王洁,王孟昭,张沂平,周建英,周晓燕,林冬梅,杨衿记,李慧,陈海泉,钟文昭,吴一龙.中国间变性淋巴瘤激酶(ALK)阳性非小细胞肺癌诊断专家共识(2013版)[J].中华病理学杂志,2013,42(6):402-406. 被引量:93

引证文献6

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部